The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

A company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, Keytruda (pembrolizumab), for adults with resectable locally advanced head and ...

Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an ...

On 16 March 2024, New Delhi Police arrested Neeraj Chauhan and others for selling fake anti-cancer drugs to patients at a ...

It boasts more than 80 programs in phase 2 or phase 3 studies. Even with a 25% success rate for these, that should translate ...

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

2. Merck Merck owns the world's best-selling drug, Keytruda, which is approved to treat many different cancers. However, the medicine will run into a patent cliff in the U.S. by 2028.

The UK’s medical research charity LifeArc has received a windfall of nearly $1.3 billion after selling a portion of its royalty interest in Merck & Co’s blockbuster cancer drug Keytruda to a ...

Its Herceptin biosimilar nearing launch, Celltrion begins work on Keytruda copySouth Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster ...

As drug development increasingly targets multiple indications, pharma companies must make strategic branding ...